Sign in Create account

Shilpa Medicare Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SHILPAMED BSE: 530549
₹1047.20
▼ -8.55 (-0.81%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
78/100
Strong
Valuation
—/100
Expensive
Momentum
55/100
Neutral

QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹20,481 Cr
PE (TTM)
111.8
Industry median 36.1 (152 companies)
Price to Book
7.9
PEG (TTM)
5.0
Institutions holding %
19.43%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
68.9
Relative return vs Sector, qtr %
83.5
Free Cash Flow
₹-28 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
56.60%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
95.79%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
55.45%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
361.73%
as of Sept. 30, 2024
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
104.52%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.31
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.25
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
19.55
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
35.29%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
28.35%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
29.26%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
6.57%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
12.43%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
9.39%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 7 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.25)
  • No Return on equity is 15% or more (9.4%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (8.7% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.8%
Low 1033.5000 · High 1075.0000
1W return
0.9%
Low 992.0000 · High 1075.0000
1M return
10.3%
Low 874.0000 · High 1075.0000
52W return
34.5%
Low 259.5000 · High 1075.0000
Lifetime High ₹1200.2500 (Aug. 5, 2015)
Lifetime Low ₹140.9500 (Dec. 19, 2011)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
1036.5
10D
1019.7
20D
982.1
50D
871.2
100D
738.3
200D
519.6

Delivery and volume

Day avg. delivery
35.1%
Week avg. delivery
37.2%
Month avg. delivery
38.8%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1051.90
Pivot
First resistance1070.30
Second resistance1093.40
Third resistance1111.80
First support1028.80
Second support1010.40
Third support987.30
Day RSI65.3
Day MFI65.2
Day MACD54.04
Day MACD signal56.00

Beta

1M1.92
3M0.97
1Y0.84
3Y1.04

Price change analysis

↑ 10.3%
Over 1 Month
LowHigh
874.001075.00
↑ 83.5%
Over 3 Months
LowHigh
566.951075.00
↑ 179.5%
Over 6 Months
LowHigh
364.151075.00
↑ 34.5%
Over 1 Year
LowHigh
259.501075.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 111.8 (own history: 42.7–148.6)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹189 Cr
Net profit (June 30, 2026)
₹65 Cr
Basic EPS (June 30, 2026)
₹3.3200

Ranks #29 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter40.13%
  • Mutual funds4.21%
  • FII/FPI11.38%
  • Other DII3.84%
  • Public40.44%

Largest holders

NameCategoryShares %Shares
VISHNUKANT CHATURBHUJ BHUTADAPromoter6.5100%12731220
DHARMAVATI BHUTADAPromoter6.3500%12415592
RAVI KUMAR INNANIPromoter4.1000%8012740
SURAJ KUMAR INANIPublic4.0100%7841390
OM PRAKASH INANIPromoter2.9300%5735382

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 40.13% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 11.08% to 11.38% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 5.15% to 4.21% in Jun 2026 qtr

8 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 117 insider trades, 48 SAST, 144 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
13 Dec 2024 PRIYA INANI Promoter group Sell 0 ₹0
26 Sep 2024 DEEPAK KUMAR INNANI Promoter group Pledge 0 ₹57.91 Cr
26 Sep 2024 DHARMAVATI BHUTADA Promoter group Pledge 0 ₹7.92 Cr
26 Sep 2024 BRIJGOPAL INNANI Promoter group Pledge 0 ₹17.16 Cr
26 Sep 2024 RAMAKANT INNANI Promoter group Pledge 0 ₹57.91 Cr
26 Sep 2024 VISHNUKANT CHATURBHUJ BHUTADA Promoter Pledge 0 ₹85.80 Cr
26 Sep 2024 OMPRAKASH INANI Promoter Pledge 0 ₹17.16 Cr
26 Sep 2024 DEEPAK KUMAR INNANI Promoter group Pledge 0 ₹57.91 Cr
26 Sep 2024 OMPRAKASH INANI Promoter Pledge 0 ₹17.16 Cr
26 Sep 2024 DHARMAVATI BHUTADA Promoter group Pledge 0 ₹7.92 Cr

All insider and SAST disclosures →

Deals (Bulk & Block)

All 142 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
23 Jan 2025 UBS PRINCIPAL CAPITAL ASIA LIMITED Block Sell 163,006 818.0500 NSE
23 Jan 2025 UBS AG Block Buy 163,006 818.0500 NSE
5 Jun 2024 PLUTUS WEALTH MANAGEMENT LLP Bulk Buy 750,000 492.3400 NSE
21 Feb 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 482,523 444.0900 NSE
21 Feb 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 482,523 443.9500 NSE
19 Feb 2024 TA FII INVESTORS LIMITED Bulk Sell 1,345,000 407.0500 NSE
19 Feb 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 578,067 404.6300 NSE
19 Feb 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 578,067 404.4800 NSE
30 Jun 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 771,081 273.0600 NSE
30 Jun 2023 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 771,081 272.9200 NSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 0.6000 — —

Corporate Actions

Full history (2 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Shilpa Antibiotics Ltd. to Shilpa Medicare Ltd.

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
5 Aug 2026 Financial Results Yes
22 May 2026 Financial Results/Dividend Yes
6 Feb 2026 Financial Results Yes
13 Nov 2025 Financial Results Yes
13 Aug 2025 Bonus —

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Insider Trading / SAST Shilpa Medicare Ltd - 530549 - Closure of Trading Window
18 Sep 2026 Company Update Shilpa Medicare Ltd - 530549 - USFDA Inspection Of Shilpa Medicare Limited, Unit VII, Analytical Services Division, Hyderabad.
12 Sep 2026 AGM/EGM Shilpa Medicare Ltd - 530549 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
11 Sep 2026 AGM/EGM Shilpa Medicare Ltd - 530549 - Shareholder Meeting / Postal Ballot-Outcome of AGM
11 Sep 2026 Company Update Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
10 Sep 2026 Company Update Shilpa Medicare Ltd - 530549 - Initiation Of NCLT Order On FTF Pharma Private Limited, A Wholly Owned Subsidiary Of Shilpa Medicare Limited.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (35.3%)
  • Low financial leverage (Debt/Equity 0.25)
  • Comfortable interest coverage (19.6x)
  • Strong revenue growth YoY (104.5%)

Weaknesses

  • Low Return on Equity (9.4%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (111.8) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Shilpa Medicare Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.